Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.

An expert discusses how rilzabrutinib, a recently FDA-approved Bruton tyrosine kinase (BTK) inhibitor, targets the autoimmune ...

What Is Wayrilz, and Why Does It Matter? Wayrilz (rilzabrutinib) is a new oral medicine for adults with a long-lasting blood clotting disorder known as chronic immune thrombocytopenia (ITP) who ...

How Does Doptelet Work in Thrombocytopenia? Thrombocytopenia is when your blood has too few platelets (also called thrombocytes). Platelets are blood cells made in the soft, spongy tissue inside your ...